CORRESPONDENCE
Real-time quantitative PCR for detection of minimal residual disease before allogeneic stem cell transplantation predicts outcome in children with acute lymphoblastic leukemia TO 
THE EDITOR
Allogeneic stem cell transplantation (SCT) is commonly used in the treatment of children with high-risk or relapsed acute lymphoblastic leukemia (ALL). However, recurrence of the initial disease is still a major problem following allogeneic SCT. In addition, transplantrelated mortality also negatively influences overall survival. Therefore, it will be of benefit to discriminate between those patients who might profit from the currently applied allogeneic SCT procedures and those for whom other treatment modalities might be more beneficial.
Recently, Knechtli et al 1 demonstrated that the presence of minimal residual disease (MRD) before SCT has a high predictive value for clinical outcome. In this study, PCR-based analysis of immunoglobulin (Ig) and T cell receptor (TCR) gene rearrangements was used to categorize MRD levels in bone marrow (BM) samples obtained 1 to 11 weeks before SCT. 1 ), but also accurate quantification of the MRD level. As indicated by Knechtli et al, 1 the level of MRD in the pre-SCT sample, determined by semi-quantitative PCR analysis, correlated well with the probability of relapse. Sensitive detection and quantification of MRD levels in pre-SCT samples by RQ-PCR analysis may further improve the predictive value for clinical outcome. We therefore investigated MRD levels by RQ-PCR analysis of Ig/TCR gene rearrangements in pre-SCT samples of ALL patients.
Seventeen children with ALL (15 precursor-B-ALL and two T-ALL) who underwent allogeneic SCT in first or second complete remission (CR) between May 1994 and October 1999 in the Leiden University Medical Center were included in this retrospective study, based on the availability of sufficient diagnosis and pre-SCT cell material ( Table 1 ). All patients were initially treated according to the ALL-8 or ALL-9 protocol of the Dutch Childhood Leukemia Study Group (DCLSG). Relapsed patients were first treated according to the relapse protocol of the DCLSG. In all patients the preparative regimen consisted of etoposide, cyclophosphamide and TBI, except for patients less than 2 years of age (5807 and 6198) who received etoposide, cyclophosphamide, and busulfan. Graft-versus-host prophylaxis (cyclosporin A 2 mg/kg i.v.) was given in all patients, except the CD34-enriched SCT. MTX (10 mg/m 2 ) on days 1, 3, and 6 was given in case of a non-depleted graft, anti-T cell antibodies were given in case of a T cell-depleted graft. None of the patients developed graftversus-host disease (GVHD), except for patient 5627 (acute GVHD grade I and limited chronic GVHD). The median follow-up after SCT was 58 months for patients in continuous CR (range 25 to 79 months). The pre-SCT sample was taken at a median of 20 days before transplantation (range 13 to 98 days).
Ig/TCR gene rearrangements were identified in diagnostic and/or relapse samples by Southern blotting, PCR heteroduplex analysis, and sequencing as previously described. 4 After sequencing of the junctional regions of the monoclonal gene rearrangements, PCR targets for MRD detection were selected based on the expected stability of the gene rearrangement and on the size and sequence of the junctional region. If available, two PCR targets were selected per patient to decrease the risk of false-negativity due to secondary or ongoing rearrangements. Oligoclonal gene rearrangements were not used as PCR target for MRD detection, unless no monoclonal Ig/TCR targets were available (patients 5627 and 5807). In the latter two patients, the major IGH gene clone (5627) and the major TCRD gene clone (5807) were used as PCR targets for MRD detection. For one patient with t(4;11), the MLL-AF4 breakpoint was identified at the DNA level and used as the sole MRD target (breakpoint kindly identified by Dr R Repp, Children's University Hospital Erlangen, Erlangen, Germany).
To determine MRD levels in pre-SCT samples by RQ-PCR, allelespecific oligonucleotide (ASO) primers and/or ASO probes were designed on the junctional region sequence of the involved Ig/TCR gene rearrangement. [2] [3] [4] RQ-PCR analysis was performed as described previously.
2,3 A 10-fold dilution series (10 −1 to 10
; in duplicate) of diagnosis or relapse DNA into mononuclear cell DNA obtained from healthy controls was used to define the sensitivity of each primer/probe set and was used for making a standard curve. The pre-SCT sample of a patient was analyzed if at least one marker had a sensitivity of at least 10 −4 . An albumin gene RQ-PCR was used to correct for the quantity and the amplifiability (quality) of the DNA in the pre-BMT samples. 2 In the pre-SCT samples of 11 patients no remaining leukemic cells could be detected (Table 1) . Of these 11 MRD-negative patients, nine patients remained in CR, including two patients (5807 and 5514) who died of transplant-related mortality 2 and 4 months after SCT (Figure 1 ). The two other pre-SCT MRD negative patients (5978 and 6584) were transplanted in first remission and relapsed approximately 4 months after SCT. RQ-PCR analysis of the post-SCT relapse samples showed that the original MRD-PCR targets (MLL-AF4 in patient 5978 and TCRG in patient 6584) were still detectable, indicating that the MRD negativity in the pre-SCT sample was not due to loss of the original MRD-PCR target. However, the tumor load detected by the V␥I-J␥2.3 MRD-PCR target in the post-SCT relapse sample of patient 6584 was relatively low (10 −2 ), indicating that the detected leukemic cells only formed a minor subclone, which might have been missed in the pre-SCT sample. Unfortunately, no other appropriate target was available for patient 6584.
In contrast to the 11 MRD-negative patients, MRD could be detected in the pre-SCT sample of six patients ( Table 1 ). Four of these six patients (67%) relapsed shortly (2 to 9 months) after SCT, whereas
Figure 1
Relapse-free survival according to the presence of MRD in the pre-SCT sample. Numbers of patients at risk are given in parentheses. 1 showing that the presence of detectable MRD levels just prior to SCT is related to a high chance of relapse. In our study, the sensitivity of the targets used was at least 10
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, whereas in the study by Knechtli et al, the sensitivity ranged between 10 −3 and 10
. This may explain the somewhat lower relapse-free survival in their MRD-negative patient group (73% vs 80%), as in some patients with low target sensitivity (between 10 −3 and 10 ), but by exception this level was measured in peripheral blood and levels in BM probably would have been higher. In contrast, the two MRD-positive patients who did not relapse had MRD levels Ͻ5 × 10 . This suggests that low levels of residual leukemic cells in BM at the time of SCT may be eliminated as a consequence of the SCT.
Although our results are derived from a limited number of patients (n = 17), they strongly suggest that sensitive and quantitative detection of MRD is required for proper identification of patients with a low risk of relapse and for making treatment decisions. This level of sensitivity (р10 ) also appeared to be essential for the MRD-based risk-group classification as proposed by the International BFM Study Group. 5 To be able to draw firm conclusions, a large-scale international RQ-PCRbased pre-SCT MRD study should be performed. Such a study, with participating centers in Germany, UK, Czech Republic, Denmark, and The Netherlands, is currently in progress.
In conclusion, sensitive and quantitative detection of MRD by RQ-PCR analysis in pre-SCT samples allows identification of patients at risk for relapse following allogeneic SCT. Our findings, together with results from Knechtli et al, 1 clearly indicate that MRD may be used as a decisive marker to define patients who might benefit from allogeneic SCT and those for whom other treatment strategies, either in the context of allogeneic SCT or not, might turn out to be more beneficial (eg SCT plus donor lymphocyte infusions 6 or graft-versus-host disease prophylaxis with low-dose cyclosporin-A).
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